Literature DB >> 17478266

Aspirin use among adults aged 40 and older in the United States: results of a national survey.

Michael Pignone1, George K Anderson, Katherine Binns, Hugh H Tilson, Steven M Weisman.   

Abstract

BACKGROUND: Aspirin is effective for the primary and secondary prevention of cardiovascular events, but its use has been suboptimal.
METHODS: Investigators performed a nationally representative Internet-based survey of U.S. consumers aged 40 and older using online databases maintained by Harris Interactive((R)) to measure use of aspirin for cardiovascular disease (CVD) prevention and factors associated with its use. Respondents reported whether they used aspirin therapy regularly for cardiovascular prevention; and provided information about their cardiovascular risk factors, discussions with their healthcare provider about aspirin therapy, and their perceptions about risks and benefits of aspirin. Objective risk of cardiovascular events was estimated using counts of self-reported risk factors. Survey results were weighted to be representative of the general U.S. population. Researchers performed bivariate and multivariate analyses to understand factors associated with aspirin use.
RESULTS: A total of 1299 adults aged 40 or older completed the survey. Mean age was 55.9, 53% were women, 79% self-identified as white, 10% African American, and 9% Latino. Current regular aspirin use for CVD prevention was reported by 41% of respondents. The factor most strongly associated with aspirin use was reporting a previous conversation with a healthcare provider about aspirin (88% aspirin use among respondents reporting such discussion versus 17% who did not report discussion; odds ratio 36.6, 95% confidence interval 25.9-51.7).
CONCLUSIONS: Aspirin use is low, even among patients at increased risk. Better provider-patient communication about aspirin prevention is associated with greater use, and should be a target for future interventions.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17478266     DOI: 10.1016/j.amepre.2007.01.010

Source DB:  PubMed          Journal:  Am J Prev Med        ISSN: 0749-3797            Impact factor:   5.043


  41 in total

Review 1.  Antihypertensive effects of aspirin: what is the evidence?

Authors:  Leonelo E Bautista; Lina M Vera
Journal:  Curr Hypertens Rep       Date:  2010-08       Impact factor: 5.369

2.  Upper Gastrointestinal Symptoms Experienced by Users of Low-Dose Aspirin (Acetylsalicylic Acid) [75-325 mg/day] for Primary and Secondary Coronary Artery Disease Prevention: Perspectives from Patient Focus Groups.

Authors:  Mary Kay Margolis; Katarina Halling; Elisabeth Sörstadius; Jørgen Næsdal; Stephanie Manson; Karin Coyne
Journal:  Patient       Date:  2009-06-01       Impact factor: 3.883

3.  Aspirin for primary cardiovascular prevention: when is it worth the risks?

Authors:  Patricia A Howard
Journal:  Hosp Pharm       Date:  2014-06

Review 4.  Review of the microscopic colitides.

Authors:  Eugene F Yen; Darrell S Pardi
Journal:  Curr Gastroenterol Rep       Date:  2011-10

5.  Genetic variation at the coronary artery disease risk locus GUCY1A3 modifies cardiovascular disease prevention effects of aspirin.

Authors:  Kathryn T Hall; Thorsten Kessler; Julie E Buring; Dani Passow; Howard D Sesso; Robert Y L Zee; Paul M Ridker; Daniel I Chasman; Heribert Schunkert
Journal:  Eur Heart J       Date:  2019-11-01       Impact factor: 29.983

6.  Aspirin Use and Mortality in Two Contemporary US Cohorts.

Authors:  Wen-Yi Huang; Sarah E Daugherty; Meredith S Shiels; Mark P Purdue; Neal D Freedman; Christian C Abnet; Albert R Hollenbeck; Richard B Hayes; Debra T Silverman; Sonja I Berndt
Journal:  Epidemiology       Date:  2018-01       Impact factor: 4.822

7.  Predicting venous thromboembolism in multiple myeloma: development and validation of the IMPEDE VTE score.

Authors:  Kristen M Sanfilippo; Suhong Luo; Tzu-Fei Wang; Mark Fiala; Martin Schoen; Tanya M Wildes; Joseph Mikhael; Nicole M Kuderer; David C Calverley; Jesse Keller; Theodore Thomas; Kenneth R Carson; Brian F Gage
Journal:  Am J Hematol       Date:  2019-08-19       Impact factor: 10.047

8.  Do clinicians recommend aspirin to patients for primary prevention of cardiovascular disease?

Authors:  Kevin Fiscella; Paul C Winters; Michael Mendoza; Gary J Noronha; Carlos M Swanger; John D Bisognano; Robert J Fortuna
Journal:  J Gen Intern Med       Date:  2015-02       Impact factor: 5.128

Review 9.  Risk assessment and aspirin use in Asian and Western populations.

Authors:  Runlin Gao; Xiaoying Li
Journal:  Vasc Health Risk Manag       Date:  2010-10-21

Review 10.  The role of aspirin in the prevention of cardiovascular disease.

Authors:  Sunitha V Ittaman; Jeffrey J VanWormer; Shereif H Rezkalla
Journal:  Clin Med Res       Date:  2014-02-26
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.